Showing results (101-110 of 228) with videos related to
Sort By:
Pageof 23
Cancers|June 24, 2022
Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell LymphomaShama Jaswal, Vanessa Sanders, Priyanka Pullarkat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.American Journal of Hematology|March 22, 2019
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registryRobert N Stuver, Niloufer Khan, Marc Schwartz, et al.Journal of the American Academy of Dermatology|February 1, 2019
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skinMeenal K Kheterpal, Julia Dai, Shamir Geller, et al.Cancer|June 22, 2010
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic scoreAdrienne A Phillips, Iuliana Shapira, Robert D Willim, et al.American Journal of Hematology|February 18, 2011
Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter studyJorge J Castillo, Brady E Beltran, Michele Bibas, et al.CA: a Cancer Journal for Clinicians|June 29, 2026
Extranodal natural killer/T-cell lymphoma: From fatal to curableJie Xiong, Yok-Lam Kwong, Laurence de Leval, et al.Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.Blood|February 9, 2026
Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy ResistanceHannah K Dorando, Jared M Andrews, Oam U Khatavkar, et al.Blood|February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCLJia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.Pageof 23